JP2020505354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505354A5 JP2020505354A5 JP2019538615A JP2019538615A JP2020505354A5 JP 2020505354 A5 JP2020505354 A5 JP 2020505354A5 JP 2019538615 A JP2019538615 A JP 2019538615A JP 2019538615 A JP2019538615 A JP 2019538615A JP 2020505354 A5 JP2020505354 A5 JP 2020505354A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- fluoro
- pyrido
- indole
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- -1 indole-2-yl Chemical group 0.000 claims 5
- BTJWAAQFFCCLEV-DDWQGHIRSA-N (2R)-3-[(1R,3R)-1-[3-[2-(3,3-difluoropropylamino)ethoxy]-6-fluoro-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCC(F)F)=CC=C1F)C(O)=O BTJWAAQFFCCLEV-DDWQGHIRSA-N 0.000 claims 1
- JMHAEPDWKOSCPH-RYUVBPIJSA-N (2R)-3-[(1R,3R)-1-[5-fluoro-2-[2-(3-fluoropropylamino)ethoxy]-3-methylpyridin-4-yl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCCF)=NC=C1F)C(O)=O JMHAEPDWKOSCPH-RYUVBPIJSA-N 0.000 claims 1
- KNSMOAXIFSMQRE-KMVLGAPJSA-N (2R)-3-[(1R,3R)-1-[6-fluoro-3-[2-(3-fluoropropylamino)ethoxy]-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCCF)=CC=C1F)C(O)=O KNSMOAXIFSMQRE-KMVLGAPJSA-N 0.000 claims 1
- OUWDZJIZWQEYKX-BIALHBOASA-N (2R)-3-[(1R,3R)-1-[6-fluoro-3-[2-[3-fluoropropyl(methyl)amino]ethoxy]-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@H](CN1[C@H](C)Cc2c([nH]c3ccccc23)[C@H]1c1c(F)ccc(OCCN(C)CCCF)c1C)C(O)=O OUWDZJIZWQEYKX-BIALHBOASA-N 0.000 claims 1
- JOFYCYZGTXIWEJ-DDWQGHIRSA-N (2R)-3-[(1R,3R)-6-fluoro-1-[6-fluoro-3-[2-(3-fluoropropylamino)ethoxy]-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@H](CN1[C@H](C)CC2=C(NC3=CC=C(F)C=C23)[C@H]1C1=C(C)C(OCCNCCCF)=CC=C1F)C(O)=O JOFYCYZGTXIWEJ-DDWQGHIRSA-N 0.000 claims 1
- BTJWAAQFFCCLEV-ANAQZDLVSA-N (2S)-3-[(1R,3R)-1-[3-[2-(3,3-difluoropropylamino)ethoxy]-6-fluoro-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCC(F)F)=CC=C1F)C(O)=O BTJWAAQFFCCLEV-ANAQZDLVSA-N 0.000 claims 1
- JMHAEPDWKOSCPH-RJYGXOMWSA-N (2S)-3-[(1R,3R)-1-[5-fluoro-2-[2-(3-fluoropropylamino)ethoxy]-3-methylpyridin-4-yl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCCF)=NC=C1F)C(O)=O JMHAEPDWKOSCPH-RJYGXOMWSA-N 0.000 claims 1
- KNSMOAXIFSMQRE-HQWTYURQSA-N (2S)-3-[(1R,3R)-1-[6-fluoro-3-[2-(3-fluoropropylamino)ethoxy]-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCCF)=CC=C1F)C(O)=O KNSMOAXIFSMQRE-HQWTYURQSA-N 0.000 claims 1
- JGCBBJPNCBOABY-QLPUUCHCSA-N (2S)-3-[(1R,3R)-6-fluoro-1-[6-fluoro-3-[2-[3-fluoropropyl(methyl)amino]ethoxy]-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@@H](CN1[C@H](C)Cc2c([nH]c3ccc(F)cc23)[C@H]1c1c(F)ccc(OCCN(C)CCCF)c1C)C(O)=O JGCBBJPNCBOABY-QLPUUCHCSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OUWDZJIZWQEYKX-IRSBVZMGSA-N FC1=CC=C(C(=C1[C@H]1N([C@@H](CC2=C1NC1=CC=CC=C21)C)C[C@@H](C(=O)O)C)C)OCCN(C([2H])([2H])[2H])CCCF Chemical compound FC1=CC=C(C(=C1[C@H]1N([C@@H](CC2=C1NC1=CC=CC=C21)C)C[C@@H](C(=O)O)C)C)OCCN(C([2H])([2H])[2H])CCCF OUWDZJIZWQEYKX-IRSBVZMGSA-N 0.000 claims 1
- 201000010255 female reproductive organ cancer Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451971P | 2017-01-30 | 2017-01-30 | |
| US62/451,971 | 2017-01-30 | ||
| US201762523695P | 2017-06-22 | 2017-06-22 | |
| US62/523,695 | 2017-06-22 | ||
| US201762560304P | 2017-09-19 | 2017-09-19 | |
| US62/560,304 | 2017-09-19 | ||
| US201762592485P | 2017-11-30 | 2017-11-30 | |
| US62/592,485 | 2017-11-30 | ||
| PCT/EP2018/052040 WO2018138303A1 (en) | 2017-01-30 | 2018-01-29 | Estrogen receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505354A JP2020505354A (ja) | 2020-02-20 |
| JP2020505354A5 true JP2020505354A5 (https=) | 2020-11-12 |
| JP6951451B2 JP6951451B2 (ja) | 2021-10-20 |
Family
ID=61223883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538615A Active JP6951451B2 (ja) | 2017-01-30 | 2018-01-29 | エストロゲン受容体モジュレーター |
Country Status (35)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109362222B (zh) | 2016-02-05 | 2021-03-19 | 益方生物科技(上海)股份有限公司 | 选择性雌激素受体降解物及其用途 |
| LT3555097T (lt) | 2016-12-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| LT3810283T (lt) * | 2018-06-21 | 2023-08-25 | F. Hoffmann-La Roche Ag | 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti |
| US20220370625A1 (en) * | 2019-09-19 | 2022-11-24 | Totus Medicines Inc. | Therapeutic conjugates |
| BR112023018286A2 (pt) | 2021-03-11 | 2023-10-31 | Janssen Pharmaceutica Nv | Lorpucitinib para uso no tratamento de distúrbios mediados por jak |
| CN115557920B (zh) * | 2022-09-22 | 2024-02-20 | 吉林奥来德光电材料股份有限公司 | 一种发光辅助材料、其制备方法及有机电致发光器件 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| ES2349762T3 (es) | 2000-08-10 | 2011-01-11 | Pfizer Italia S.R.L. | Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden. |
| US8008076B2 (en) * | 2004-04-27 | 2011-08-30 | Chugai Seiyaku Kabushiki Kaisha | Method of producing a nucleic acid encoding an antibody |
| TW200716628A (en) | 2005-03-22 | 2007-05-01 | Astrazeneca Ab | Novel compounds |
| FR2884252B1 (fr) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
| AR058223A1 (es) | 2005-11-25 | 2008-01-23 | Palau Pharma Sa | Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US20120157402A1 (en) * | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
| MX373926B (es) | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| US20120157401A1 (en) | 2009-05-27 | 2012-06-21 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| JP6112625B2 (ja) | 2011-12-14 | 2017-04-12 | セラゴン ファーマシューティカルズ，インク． | フッ素化したエストロゲン受容体モジュレーターおよびその使用 |
| TWI653235B (zh) * | 2013-05-28 | 2019-03-11 | 阿斯特捷利康公司 | 作為抗癌劑之吲哚衍生物 |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| BR112015030595A2 (pt) | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| EP3233818A1 (en) | 2014-12-18 | 2017-10-25 | F. Hoffmann-La Roche AG | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
| CN107406424B (zh) | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 雌激素受体调节剂及其用途 |
| KR102785474B1 (ko) | 2014-12-18 | 2025-03-26 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| EP3303326B1 (en) | 2015-05-26 | 2020-12-16 | H. Hoffnabb-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
| KR20180012853A (ko) | 2015-06-16 | 2018-02-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도 |
| CN106518768B (zh) | 2015-09-15 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的应用 |
| KR102710603B1 (ko) | 2015-10-01 | 2024-09-27 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
| US10399939B2 (en) | 2015-11-09 | 2019-09-03 | Genentech, Inc. | Tetrahydronaphthalene estrogen receptor modulators and uses thereof |
| US10519148B2 (en) | 2015-11-12 | 2019-12-31 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| MX2018007844A (es) | 2015-12-22 | 2019-01-21 | Jiangsu Hengrui Medicine Co | Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo. |
| US9969732B2 (en) | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| US10125135B2 (en) | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
| WO2017192991A1 (en) | 2016-05-06 | 2017-11-09 | Xavier University Of Louisiana | Selective estrogen receptor down-regulators (serds) |
| WO2018001232A1 (zh) | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| WO2018019793A1 (en) * | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
| CN107814798B (zh) | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| WO2018053354A1 (en) | 2016-09-15 | 2018-03-22 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| TWI735681B (zh) | 2016-10-24 | 2021-08-11 | 瑞典商阿斯特捷利康公司 | 化合物 |
| BR102016024814A2 (pt) | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| EP3555064B9 (en) | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| KR102276022B1 (ko) | 2016-12-16 | 2021-07-13 | 일라이 릴리 앤드 캄파니 | 돌연변이체 idh1 및 idh2 억제제로서의 7-페닐에틸아미노-4h-피리미도[4,5-d][1,3]옥사진-2-온 화합물 |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| LT3555097T (lt) | 2016-12-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai |
| CA3045224A1 (en) | 2016-12-16 | 2018-06-21 | Basf Se | Pesticidal compounds |
| ES2866152T3 (es) | 2017-01-30 | 2021-10-19 | Chiesi Farm Spa | Derivados de tirosina amida como inhibidores de la Rho-quinasa |
-
2018
- 2018-01-29 PT PT187050976T patent/PT3494116T/pt unknown
- 2018-01-29 SI SI201830022T patent/SI3494116T1/sl unknown
- 2018-01-29 CR CR20190379A patent/CR20190379A/es unknown
- 2018-01-29 SG SG11201906767XA patent/SG11201906767XA/en unknown
- 2018-01-29 JO JOP/2019/0183A patent/JOP20190183B1/ar active
- 2018-01-29 KR KR1020197025253A patent/KR102246668B1/ko active Active
- 2018-01-29 MX MX2019008438A patent/MX2019008438A/es unknown
- 2018-01-29 AU AU2018211495A patent/AU2018211495B2/en active Active
- 2018-01-29 PL PL18705097T patent/PL3494116T3/pl unknown
- 2018-01-29 LT LTEP18705097.6T patent/LT3494116T/lt unknown
- 2018-01-29 ES ES18705097T patent/ES2766249T3/es active Active
- 2018-01-29 US US15/881,962 patent/US10221173B2/en active Active
- 2018-01-29 WO PCT/EP2018/052040 patent/WO2018138303A1/en not_active Ceased
- 2018-01-29 TN TNP/2020/000009A patent/TN2020000009A1/en unknown
- 2018-01-29 JP JP2019538615A patent/JP6951451B2/ja active Active
- 2018-01-29 HU HUE18705097A patent/HUE047761T2/hu unknown
- 2018-01-29 UA UAA201909412A patent/UA125043C2/uk unknown
- 2018-01-29 MY MYPI2019004298A patent/MY196317A/en unknown
- 2018-01-29 RS RS20200018A patent/RS59770B1/sr unknown
- 2018-01-29 MA MA052555A patent/MA52555A/fr unknown
- 2018-01-29 EP EP19203383.5A patent/EP3689873B1/en active Active
- 2018-01-29 CN CN201880008715.8A patent/CN110214140B/zh active Active
- 2018-01-29 EP EP18705097.6A patent/EP3494116B1/en active Active
- 2018-01-29 ES ES19203383T patent/ES2931320T3/es active Active
- 2018-01-29 TW TW107103088A patent/TWI794205B/zh active
- 2018-01-29 SM SM20200010T patent/SMT202000010T1/it unknown
- 2018-01-29 PE PE2019001434A patent/PE20191500A1/es unknown
- 2018-01-29 DK DK18705097.6T patent/DK3494116T3/da active
-
2019
- 2019-01-31 US US16/263,683 patent/US10590132B2/en active Active
- 2019-07-15 CL CL2019001991A patent/CL2019001991A1/es unknown
- 2019-07-16 DO DO2019000183A patent/DOP2019000183A/es unknown
- 2019-07-17 ZA ZA2019/04696A patent/ZA201904696B/en unknown
- 2019-07-25 IL IL268263A patent/IL268263B/en unknown
- 2019-07-26 NI NI201900080A patent/NI201900080A/es unknown
- 2019-07-26 PH PH12019501724A patent/PH12019501724A1/en unknown
- 2019-08-16 CO CONC2019/0008941A patent/CO2019008941A2/es unknown
- 2019-08-28 EC ECSENADI201962381A patent/ECSP19062381A/es unknown
-
2020
- 2020-01-08 CY CY20201100014T patent/CY1122731T1/el unknown
- 2020-01-29 US US16/775,781 patent/US11046689B2/en active Active